Clinical TrialJul 15, 2026, 07:01 AM
INmune Bio's XPro1595 Study Links TBI to Alzheimer's
AI Summary
INmune Bio announced the publication of a new peer-reviewed preclinical study in the Journal of Neurotrauma, funded by the Department of Defense. The study found that traumatic brain injury (TBI) raised levels of inflammatory cytokine TNF and neurotoxic amyloid beta (Aβ42), which are central to Alzheimer's disease. Treatment with the company's lead neuroinflammation candidate, XPro1595, prevented this injury-induced rise in amyloid pathology and improved early cognitive and pain-related outcomes, reinforcing its potential in neurodegenerative diseases.
Key Highlights
- New peer-reviewed preclinical study on XPro1595 published in Journal of Neurotrauma.
- Study found TBI raised inflammatory cytokine TNF and neurotoxic amyloid beta (Aβ42).
- XPro1595 prevented injury-induced rise in amyloid pathology in 3xTg-AD mice.
- Treated animals showed improved learning, memory, and reduced pain within one week.
- XPro1595 selectively neutralizes soluble TNF (sTNF) without affecting transmembrane TNF.
- Study reinforces XPro1595's mechanism in interrupting neuroinflammation driving Alzheimer's pathology.
- Findings suggest a role for XPro1595 in treating TBI-related Alzheimer's risk.
Price Impact
More from INMB